Refinement of biomarker assessment—including co-expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Lymphocyte Activation Gene 3 (LAG3), or tumor mutational burden (TMB) status—may help identify responders more accurately (92). The gene discussed is LAG3; the disease is neoplasm.